Grew gross revenue 51% sequentially to $29.1 million in Q3 2021 from Q2 2021 and 31% from the same prior year period Grew net revenue 39% sequentially to $20.3 million in Q3 2021 from Q2 2021 and 13% from the same prior year period Grew adult-use r
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES. TORONTO--(BUSINESS WIRE)--$HMPS #Cannabis--Hempsana Holdings Ltd. (the
SAN CARLOS, Calif. & CHICAGO--(BUSINESS WIRE)--FBN® - Farmers Business Network, the farmer-to-farmer network of more than 25,000 farmers who farm more than 70 million acres globally, today announced it has hired agriculture policy veteran Ken Barbic as H
EDMONTON, Alberta & SAN DIEGO, Calif.--(BUSINESS WIRE)--#48HourDiscovery--48Hour Discovery Inc and RayzeBio today announced the companies have entered a strategic research collaboration to discover and develop novel peptide-based radiopharmaceuticals for
Tilray urges shareholders to vote today in support of long-term value creation NEW YORK & LEAMINGTON, Ontario--(BUSINESS WIRE)--Tilray, Inc. (“Tilray” or the “Company”) (NASDAQ | TSX: TLRY), a leading global cannabis-lifestyle and consumer packag
ISLAND PARK, Id.--(BUSINESS WIRE)--Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) announces financial results for Q2 2021. Highlights of Six Months Ended March 31, 2021 Sales and Product Offerings - Re
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will be participating i
SASKATOON, Saskatchewan--(BUSINESS WIRE)--Nutrien Ltd (TSX and NYSE: NTR) announced today plans to release second quarter earnings results on Monday, August 9, 2021, after market close. Nutrien will host a conference call the following day, Tuesday, Augus
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced the scaling up of its European operations and research activities wi
Webinar on Friday, July 16th at 12 p.m. Eastern Time FOTIVDA recently surpassed 300 total commercial prescriptions since its March 22, 2021 launch BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biophar
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.